Reading Time: 6 minutes On 29th September 2022 AMX0035, a treatment for Motor Neurone Disease (MND) was approved by the Food and Drug Administration (FDA) in the United States. Two countries have approved AMX0035, with Canada conditionally approving the drug, known there as Albrioza, back in June 2022. The Canadian approval is dependent on the results of the ongoing…
Reading Time: 6 minutes The recent publication of the results from the Phase 3 Tofersen trial, an experimental gene therapy for the treatment of MND in people with a change in the gene that instructs the SOD1 protein, has provided increasing confidence that Tofersen is having a beneficial effect in people living with SOD1 MND. This and the development…
Reading Time: 4 minutes Every year at the European Network to Cure ALS (ENCALS) meeting, the Young Investigator award is presented to the brightest and best young scientist in MND research who made significant achievements and have the most promising career in MND research ahead of them. The prestigious award is given for outstanding research, which challenges existing ideas…
Reading Time: < 1 minute Members of the research recently attended the 20th European Network for the Cure of Amyotrophic Lateral Sclerosis (ENCALS) meeting in Edinburgh, Scotland, on the 1-3rd of June 2022. Here they chat with Head of Research Dr Nick Cole about the meeting, being back in-person and their research highlights. The team will be posting more highlights from the…
Reading Time: 6 minutes This year is set to be an exciting time for MND research, and we are especially hopeful that MND clinical trials will take centre stage in the coming months. During 2022 we are expecting new trials to begin recruitment in the UK, other trials to readout their results and decisions announced from authorising bodies for…
Reading Time: 4 minutes My name is Oscar Wilkins and I am a PhD student working with Professors Pietro Fratta (recipient of a MND Association Research Fellowship) and Jernej Ule. Recently, in collaboration with Sarah Hill and Michael Ward, a team led by PhD student Anna-Leigh Brown, postdoctoral researcher Matt Keuss and myself uncovered a promising new target for…
Reading Time: 5 minutes “The search for new drugs to help MND patients is a long and challenging one, but it is one where we are beginning to see hope for the future emerging on several fronts. New Artificial Intelligence (AI) data analysis techniques and larger, more detailed collections of patient data have been pivotal in these advances.” Dr…
Reading Time: 7 minutes Global biotechnology company Biogen has announced plans to make tofersen, a potential treatment for people whose MND is believed to be driven by mutations in the SOD1 gene, available to more people on an early access programme. Biogen have also revealed that they are conducting a new Phase 3 clinical trial of tofersen in those…
Reading Time: 3 minutes We were delighted to be invited to take part in ‘Star Cells’, a science-inspired performance art project in support of the Motor Neurone Disease Association, one of the events held last week to mark Global MND Awareness Day on 21 June. Inspired by the exciting and ground-breaking research into neuroscience taking place at the Francis…
Reading Time: 5 minutes A potential link between exercise and MND has long been a topic of conversation and debate. Several studies have been carried out, but the discovery of a link has not been conclusively shown. Some have shown an association, but it is important to note that association is very different from cause. Studies that use questionnaire-based…
